



Mariee Grima
John B Dixon

Obesity

Recommendations for management in general practice and beyond

Background

It is well recognised that Australia has one of the highest prevalences of overweight and obesity in the developed world, and that this is the greatest contributing factor, along with ageing, to the chronic disease burden in our society. Predictions are confronting; close to 80% of Australian adults are predicted to be obese by the year 2025.

The determinants of obesity are multifactorial and are influenced by early life environments as well as genetics. Prevention is failing due to many factors including a poor understanding of these determinants as well as reluctance to act at a government/community level.

Objective

This article aims to provide a practical approach to weight management in general practice with a focus on some of the more intensive interventions beyond the first line lifestyle modification advice.

Discussion

General practitioners are often well placed to identify overweight and obesity. Patient engagement in management is critical, as for any chronic disease. Treatment needs to be evidence based and focused on a broad range of health outcomes, not simply on weight. Intensive interventions to potentiate weight loss may involve use of very low energy diets, pharmacotherapy and bariatric surgery. Referral to specialist weight assessment and management clinics, where available may be appropriate, particularly for complex cases with more severe comorbidity.

Keywords

overweight; obesity; weight loss



Obesity is a complex, chronic, relapsing condition and, along with ageing, is the greatest contributing factor to chronic disease burden in our society. It is well recognised that Australia has one of the highest prevalences of overweight and obesity in the developed world, affecting over 60% of adults and 25% of children and adolescents; this figure is predicted to increase to close to 80% of adults by the year 2025.^{1,2} One-quarter of Australian adults are considered to be obese (body mass index [BMI] >30 kg/m²), and numbers affected by this more severe form of overweight are rising exponentially.^{2,3} The economic burden associated with the epidemic proportions of obesity in Australia has been attributed to the overall healthcare cost of \$58.2 billion in 2008, with direct healthcare costs in excess of \$8 billion per year.⁴ These figures are only likely to increase, further straining health services.

The major determinants of obesity are multifaceted, surprisingly poorly understood and extend well beyond simplistic explanations about high energy Western diets and obligatory reductions in human movement.⁵ The interplay between humans and the environment, influenced by genes, epigenetic default metabolic programming, the intrauterine environment and early infant feeding practices set the scene in the early years for weight trajectory throughout life.⁶ The list of comorbidities associated with both excess weight and the metabolic consequences of obesity is extensive and encompasses chronic disease, as well as functional and psychosocial disability (*Table 1*).⁷ Furthermore, it is well established that increasing levels of obesity are associated with poor overall quality of life and increased morbidity and mortality.⁸

Prevention of obesity is failing for many reasons including: a poor understanding of the obesity determinants and evidence regarding what influences them, political inertia associated with a modern market economy, and philosophical views of personal responsibility versus regulation and whole of community involvement. Treatment strategies for obesity should ideally follow a chronic disease model of care with a patient centred focus and initial use of lifestyle and micro-environmental interventions, with escalation to more intensive interventions as dictated by the severity of disease and response to therapy.^{9,10} Treatment needs to be evidence based and focused on a broad range of health outcomes, not simply on weight. Excellent management of medical, psychological and physical co-morbidity are critical to engaging



patients in weight loss interventions, improving function and quality-of-life, and reducing morbidity and mortality. It is also important to note that not all methods to treat obesity are equally effective. This article addresses first-line treatment with lifestyle modification in general practice and then focusses on appropriate use of more intensive treatments to support weight loss as well as identifying indications for referral to specialist weight management clinics.

Weight management in general practice

General practitioners are often the first healthcare providers to identify overweight or obesity. Treatment should be individualised with careful consideration given to the severity of the problem and associated complications using the 5As approach for weight management: Ask and Assess, Advise, Assist and Arrange (*Table 2*).⁷

It is important to assess the level of obesity by BMI, distribution of weight (waist circumference), and the extent of co-morbidity, in order to provide effective treatment and assess level of disease risk (*Table 3*).^{7,11,12} Patient engagement as a central agent in management is fundamental. The therapeutic partnership is critical in delivering long term health outcomes as for any other chronic disease.⁹

Optimal management of obesity in time poor general practice requires a team care approach involving those specifically trained and experienced in obesity management. These may include dietitians, practice nurses, commercial weight management programs, exercise physiologists and psychologists.⁷ General practitioners are encouraged to identify, engage and regularly communicate with local weight management providers and to refer those with resistant severe complex obesity for specialised assessment and management recommendations.⁷ The evidence demonstrating the benefits of weight loss is well documented. Modest weight loss of 5–10% of starting weight can result in significant health benefits, with substantial weight loss offering even greater improvements in obesity related comorbidities. Weight loss for most isn't easy. Regulation of body weight is carefully controlled by a range of highly efficient homeostatic mechanisms that work to prevent weight loss rather than to protect against weight gain.^{13–15} In addition, factors predisposing an obese patient to weight gain – such as certain medications, smoking status, a patient's weight history and readiness to change – can significantly impact on weight loss success.⁷ These factors and mechanisms challenge successful weight loss and long term weight maintenance for the obese patient and should be taken into careful consideration, especially when planning interventions.

Despite these difficulties, lifestyle interventions remain the first line treatment for overweight and obesity. General practitioners should make patients aware of the health risks associated with increases in BMI and the benefits that can be derived from lifestyle change, even when independent of weight loss.⁷ The initial approach to weight loss and lifestyle change should include an emphasis on healthy eating with a subsequent reduction in energy intake, in line with the Australian Dietary Guidelines 2013.¹⁶ Increasing levels of physical activity and reductions in sedentary behaviour should also be encouraged.^{7,12,16,17} Psychological therapies to support behaviour change may also be of assistance.

Intensive interventions

Intensive interventions to potentiate weight loss may involve use of very low energy diets (VLEDs), pharmacotherapy and bariatric surgery. A summary of the weight loss effects of each weight management intervention is shown in *Figure 1*.

Table 1. Health risks associated with overweight and obesity in adults

Body system	Health risk
Cardiovascular	Stroke Coronary heart disease Cardiac failure Hypertension
Endocrine	Type 2 diabetes Polycystic ovary syndrome
Gastrointestinal	Non-alcoholic fatty liver disease Gallbladder disease Pancreatic disease Gastro-oesophageal reflux disease Cancers of the bowel, oesophagus, gall bladder and pancreas
Genitourinary	Chronic kidney disease – glomerulopathy End-stage renal disease Kidney cancer Kidney stones Prostate cancer Stress urinary incontinence (women) Sexual dysfunction (men)
Pulmonary	Obstructive sleep apnoea Obesity hypoventilation syndrome Asthma
Musculoskeletal	Osteoarthritis – especially the knees Spinal disc disorders Lower back pain Disorders of soft tissue structures such as tendons, fascia and cartilage Foot pain Mobility disability (particularly in older adults)
Reproductive health	Menstrual disorders Miscarriage and poor pregnancy outcome Infertility/sub-fertility Breast cancer (postmenopausal women) Endometrial cancer Ovarian cancer
Mental health	Depression Eating disorders – binge eating disorder Reduced health – related quality of life

Adapted with permission from National Health and Medical Research Council. Clinical practice guidelines for the management of overweight and obesity in adults, adolescents and children in Australia. Canberra: NHMRC, 2013



Table 2. The 5 As overweight and obesity management model for adults and post-pubertal adolescents⁷

Establish a therapeutic relationship, communicate and provide care in a way that is person centred, culturally sensitive, non-directive and non-judgemental					
Ask and Assess	Standard care		Active management		
	BMI <25	BMI 25–29.9	BMI 30–34.9	BMI 35–39.9	BMI >40
	Routinely assess and monitor BMI and waist circumference (WC)	Routinely assess and monitor BMI and WC Discuss if BMI and/or WC increasing Screen for and manage comorbidities	Routinely assess and monitor BMI and WC Discuss health issues Screen for and manage comorbidities Assess other factors related to health risk Blood pressure, lipid profile, fasting glucose, liver function tests, and ask about symptoms of sleep apnoea and depression		
Advise	Promote benefits of healthy lifestyle Explain benefits of prevention of weight gain and maintenance of healthy weight		Promote benefits of healthy lifestyle Explain benefits of weight management		
Assist			Assist in setting up weight loss program: <ul style="list-style-type: none"> • Advise lifestyle interventions • Based on comorbidities, risk factors and weight history, consider adding intensive weight loss interventions (eg. VLEDs, pharmacotherapy, bariatric surgery) • Tailor the approach to the individual • Refer to multidisciplinary team for specialist treatment recommendations. Suitable patients include those with severe complex obesity for example those with a BMI >40, BMI >35 with any serious comorbidity, and those BMI 30–35 with serious comorbidity and a positive weight trajectory. 		
Arrange			Review and monitoring Long term weight management Referral to specialist weight management clinic if indicated		

Very low energy diets

VLEDs (<800 kcal/day or <3350 kJ/day) are indicated for use in patients with a BMI >30 or BMI >27 with obesity related comorbidities. When used under the medical supervision of a GP and dietician, VLEDs are able to induce rapid weight loss and have been shown to achieve an average weight loss of 18–20% with better sustained weight reduction.¹⁸ In addition to weight loss effects, the rapid weight loss offered by VLEDs has been shown to improve glycaemic control in patients with type 2 diabetes, improve blood pressure and reduce total cholesterol. VLEDs involve replacing all meals with a specific meal replacement formula (additional food can be carefully added) during the intensive early phase. These high protein-low carbohydrate diets induce fat burning and mild ketosis, which results in suppression of hunger and promotion of satiety. Treatment duration with a VLED is generally 8–12 weeks, however, safe year-long use under strict medical supervision has been reported.¹⁹ In addition, VLEDs are safe and effective when used to assist with long term weight maintenance in either an intermittent or on-demand fashion.²⁰

VLEDs may not be suitable for use for all obese patients and it is important to consider the costs associated with purchasing suitable

nutritionally complete meal replacements. VLEDs are contraindicated for use in pregnant or lactating women, infants, children, adolescents (under 18 years), elderly (over 65 years), patients with a history of psychological disturbances, alcohol misuse or drug abuse, in the presence of porphyria, recent myocardial infarction or unstable angina.⁷ Monitoring and support of patients on VLEDs is required for success (Table 4). Training on the use of VLEDs is available and should be sought by practices wanting to effectively utilise this intensive intervention with suitable overweight or obese patients.

Pharmacotherapy

Pharmacotherapy for the treatment of obesity should be considered for use as an adjunct to lifestyle intervention in patients with a BMI >30 or BMI >27 with obesity related comorbidities.²¹ Weight loss medications used in the treatment of obesity can act centrally to increase levels of satiety or act on the gastrointestinal tract to restrict nutrient absorption. Table 5 describes the pharmacological agents that may be used to treat obesity.^{7,17} Care, consideration and close monitoring is essential when prescribing these medications. The United States Food and Drug Administration (FDA) has recently approved two new medications: lorcaserin and phentermine-topiramate.

Table 3. Classification of disease risks* by WHO BMI classification and WC thresholds

BMI (kg/m ²)	Classification	Men WC 94–102 cm Women WC 80–88 cm	Men WC >102 cm Women WC >88 cm
18.5–24.9	Normal weight [†]	–	–
25–29.9	Overweight	Increased	High
30–34.9	Obese class I	High	Very high
35–39.9	Obese class II	Very high	Very high
≥40.0	Obese class III	Extremely high	Extremely high

* Disease risk for type 2 diabetes, hypertension and cardiovascular disease

[†] Increased WC can also be a marker for increased risk even in persons of normal weight

Reproduced from the Scottish Intercollegiate Guidelines Network (SIGN). Management of obesity. A national clinical guideline. Edinburgh: SIGN; Year. (SIGN publication no. 115). [cited 10 July 2013]. Available from URL: <http://www.sign.ac.uk>




Figure 1. Average weight loss of subjects completing a minimum 1 year weight management intervention; based on review of 80 studies (N=26 455; 18 199 completers [69%])²⁶

These medicines are not yet approved for use by the Therapeutic Goods Administration (TGA) in Australia.²¹ It is important to note that the safety and efficacy of co-administration of lorcaserin or phentermine-topiramate with other products for weight loss, and the effects of these medications on cardiovascular morbidity and mortality, have not yet been established.

Surgery

Bariatric surgery should be considered for patients with a BMI >40 or with a BMI >35 with obesity related comorbidities.²² Bariatric surgery is the most effective available treatment for obesity in terms of achieving and maintaining substantial weight loss long term.²³ The three most commonly performed procedures in Australia include laparoscopic adjustable gastric banding (LAGB), Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG). We are now starting to learn about how alterations to the gastrointestinal tract, induced by bariatric surgery, reduce hunger, increase satiety and confer other metabolic benefits as well as sustained weight loss.^{24,25}

Table 4. VLEDs: Adverse effects, monitoring and review in general practice^{7,19}

Adverse effects	Common	Sensitivity to cold, dry skin, temporary rash, temporary hair loss, postural hypotension, dizziness, fatigue, diarrhoea, constipation, muscle cramps, bad breath, irritability, menstrual disturbances
	Rare and serious	Gallstones, gout, sodium or potassium imbalance, temporary changes in liver enzyme levels, reduced bone mineral density
Monitoring	Medical	Medical history, physical examination, height, weight, waist and hip circumference, BMI, blood pressure, pulse, electrocardiogram
	Blood biochemistry*	Full blood count, iron studies, electrolytes, creatinine, uric acid, liver function tests, lipid profile and urinalysis including ketones, pH and microalbuminuria
	Medications	Anti-diabetic agents (sulphonylureas, thiazolidinediones, insulin), warfarin, lithium, diuretics, anti-psychotics, anti-convulsants (valproate, gabapentin, carbamazepine)
Review frequency	GP	Each week for 4 weeks, then fortnightly for remainder of intensive phase
	Dietician	

* Tests carried out on patients should be completed at the beginning of a VLED. An ECG is only needed if there is another indication. Blood biochemistry may be repeated at 6 weeks if indicated by the patients accompanying medical condition and for all after 3 months if they intend to continue with the intense VLED program.



To date, the long term safety of LAGB and RYGB has been documented, however evidence on long term safety is lacking for the SG. Each procedure is accompanied by its own advantages and disadvantages, and these need to be taken into consideration when assessing a patient's suitability for surgery (Table 6). Current medical and psychological comorbidities, as well as ability to provide informed consent, will all influence a patient's suitability for

undergoing a particular procedure.⁷ Patients considering bariatric surgery should be made aware of the commitment to indefinite post-surgical care and long term monitoring from an experienced team.

Specialist weight management clinics

Unfortunately, specialist weight assessment and management clinics for complex severe obesity are not broadly available, but with the

Table 5. Weight loss and other medications for treatment of obesity

Action	Medication	Indications	Common adverse effects	Mean weight loss (compared with placebo)	Notes
Dopaminergic agonist	Phentermine	Management of obesity as a short term adjunct to medically managed comprehensive weight reduction regimen in obesity of BMI >30 or BMI 25–29.9 if associated with comorbidities	Palpitations, tachycardia, hypertension, precordial pain, central nervous system stimulation, headache, gastrointestinal upset including constipation, dry mouth, altered taste, micturition disturbance, rash, impotence, libido change, facial oedema	3.6 kg (CI: 6.0–0.6) following 2–24 weeks treatment ²⁶	Approved only for short term use – up to 3 months
Pancreatic and gastric lipase inhibitor	Orlistat	Treatment of obese patients with a BMI >30 and overweight patients with a BMI >27 with associated comorbidities	Gastrointestinal upset including oily spotting, flatulence, faecal urgency, loose stools, nausea, dyspepsia, reduced vitamin absorption, headache, kidney stones	2.9 kg (CI: 3.5–2.3) at 1 year ²⁷	Low fat diet should be followed
Biguanide	Metformin	Treatment of type 2 diabetes	Gastrointestinal upset, taste disturbance, vitamin B12 depletion, liver function test abnormality, hepatitis, skin reaction	Women of reproductive age prone to infertility: 0.68 BMI (CI: 1.13–0.24) following 35 days to 6 months treatment ²⁸ Without diabetes treated with atypical anti-psychotics: 4.8% body weight (CI: 8.0–1.6) following 12–14 weeks treatment ²⁹	Not approved for the treatment of obesity
Glucagon-like peptide agonists	Exenatide (Byetta)	Treatment of type 2 diabetes	Gastrointestinal upset, hypoglycaemia, exenatide antibody formation, decreased appetite, headache, hyperhidrosis, jitteriness, asthenia, injection site reaction, nasopharyngitis, upper respiratory tract infection, back pain, cough	Without diabetes: 3.2 kg (CI: 4.3–2.1) following minimum 20 weeks treatment ³⁰ With diabetes: 2.8 kg (CI: 3.4–2.3) following minimum 20 weeks treatment ³¹	Byetta and Victoza are not yet approved for the treatment of obesity
	Liraglutide	Treatment of type 2 diabetes	Gastrointestinal upset, anorexia, dyspepsia, eructation, gastroesophageal reflux disease, hypoglycaemia, decreased appetite, headache, injection site reaction, upper respiratory tract infection, antibody formation, urticaria, oedema, pancreatitis, thyroid neoplasm, goitre, increased blood calcitonin, renal failure		

**Table 5. Weight loss and other medications (continued)**

Serotonin 2C receptor agonist	Lorcaserin	Management of obesity as an adjunct to medically managed comprehensive weight reduction regimen in obesity of BMI >30 or in overweight of BMI >27 if associated with comorbidities	In non-diabetic patient: headaches, dizziness, fatigue, nausea, dry mouth, constipation In diabetic patient: hypoglycaemia, headache, back pain, cough, fatigue	3.23 kg (CI: 3.75–2.70) at 1 year ³²	Lorcaserin and Qsymia are both FDA approved, but not yet approved by the TGA for use in Australia
Combined dopaminergic agonist and antiepileptic	Phentermine and topiramate	Management of obesity as an adjunct to medically managed comprehensive weight reduction regimen in obesity of BMI >30 or in overweight of BMI >27 if associated with comorbidities	Paresthesia in the hands, arms, feet, or face, dizziness, dysgeusia, insomnia, constipation, dry mouth, tachycardia, suicidal thoughts	7.5 mg phentermine plus 46.0 mg topiramate: 8.1 kg (CI: 8.5–7.1) following 56 weeks treatment ³³ 15 mg phentermine plus 92 mg topiramate: 10.2 kg (CI: 10.4–9.3) following 56 weeks treatment ³³	

emergence of new drugs, devices and surgical procedures, as well as ever increasing patient numbers; assessment by teams skilled in this area is becoming more necessary. Some major hospitals offer outpatient 'specialist weight management' or 'metabolic' clinics; however, access is often impeded by very long waiting lists. Medicare Locals may provide a forum for exploring delivery gaps in regional areas particularly. Specialised weight management services would provide advice to the GP similar to that expected from cardiac or diabetes referrals such as an evaluation of the patients, advice regarding the treatment options and a proposal for ongoing shared care. Severe obesity is a serious complex chronic disease and requires this level of expertise and support to optimise health outcomes.

Conclusion

General practitioners are in a key position to provide support, advocacy and coordinate management for obese patients. The use of intensive interventions should be considered and utilised within the general practice setting and, where indicated, complex obese patients should be referred to specialist weight assessment and management clinics.

Key points

- Obesity is a complex chronic relapsing condition requiring ongoing management and monitoring from medical and other allied health professionals.
- Maintained weight loss is a primary, but not the sole, consideration when treating obesity.
- General practitioners are encouraged to consider the timely use of more intensive treatments to support weight loss beyond that of first line treatment with lifestyle modification.
- Referral and liaising with specialist weight assessment and management clinics for complex cases can enhance outcomes.

Authors

Mariee Grima BSc (Nutr), MDiet, is an Accredited Practising Dietitian and research assistant, Human Neurotransmitters & Clinical Obesity Research Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, VIC. mariee.grima@bakeridi.edu.au

John B Dixon MBBS, PhD, FRACGP, FRCP(Edin), is NHMRC Senior Research Fellow and Head, Clinical Obesity Research, Vascular and Hypertension Division, Baker IDI Heart and Diabetes Institute, Department of General Practice, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC.

Competing interests: John B Dixon is a board member of Nestle Australia and has received payment for consultancy from Allergan Inc and Bariatric Advantage. John B Dixon has received payments for lectures from iNova Pharmaceuticals and Merck Sharp & Dohme and for development of educational presentations from iNova Pharmaceuticals, and travel expenses from GI Dynamics.

Provenance and peer review: Commissioned; externally peer reviewed.

References

1. Haby MM, Markwick A, Peeters A, Shaw J, Vos T. Future predictions of body mass index and overweight prevalence in Australia, 2005–2025. *Health Promot Int* 2011;27:250–60.
2. Walls HL, Magliano DJ, Stevenson CE, et al. Projected progression of the prevalence of obesity in Australia. *Obesity (Silver Spring)* 2011;20:872–78.
3. Walls HL, Wolfe R, Haby MM, et al. Trends in BMI of urban Australian adults, 1980–2000. *Public Health Nutr* 2009;13:631–38.
4. Obesity Working Group. National Preventive Health Taskforce. Australia: the healthiest country by 2020. Technical Report No 1. Obesity in Australia: a need for urgent action. Available from: [http://www.preventativehealth.org.au/internet/preventativehealth/publishing.nsf/Content/E233F8695823F16CCA2574DD00818E64/\\$File/obesity-jul09.pdf](http://www.preventativehealth.org.au/internet/preventativehealth/publishing.nsf/Content/E233F8695823F16CCA2574DD00818E64/$File/obesity-jul09.pdf) [Accessed 13 July 2013].
5. McAllister EJ, Dhurandhar NV, Keith SW, et al. Ten putative contributors to the obesity epidemic. *Crit Rev Food Sci Nutr* 2009;49:868–913.
6. Gluckman PD, Hanson MA. Developmental and epigenetic pathways to obesity: an evolutionary-developmental perspective. *Int J Obes (Lond)* 2008;32(Suppl 7):S62–71.



7. National Health and Medical Research Council. Clinical practice guidelines for the management of overweight and obesity in adults, adolescents and children: draft clinical practice guidelines for primary healthcare professionals. Canberra: NHMRC, 2013.
8. Cameron AJ, Magliano DJ, Dunstan DW, et al. A bi-directional relationship between obesity and health-related quality of life: evidence from the longitudinal AusDiab study. *Int J Obes (Lond)* 2012;36:295–303.
9. Wagner EH. Chronic disease management: what will it take to improve care for chronic illness? *Eff Clin Pract* 1998;1:2–4.
10. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. *N Engl J Med* 2005;353:2111–20.
11. National Health and Medical Research Council. Overweight and obesity in adults: a guide for general practitioners. Canberra: NHMRC, 2003.
12. SIGN. Management of obesity. A national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network, 2010.
13. Sumithran P, Proietto J. The defence of body weight: a physiological basis for weight regain after weight loss. *Clin Sci (Lond)* 2013;124:231–41.
14. Schwartz MW, Woods SC, Seeley RJ, Barsh GS, Baskin DG, Leibel RL. Is the energy homeostasis system inherently biased toward weight gain? *Diabetes* 2003;52:232–38.
15. Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. *N Engl J Med* 2011;365:1597–604.
16. National Health and Medical Research Council, Department of Health and Ageing. Australian dietary guidelines. Canberra: NHMRC, 2013.
17. National Health and Medical Research Council. Clinical practice guidelines for the management of overweight and obesity in adults. Canberra: NHMRC, 2003.
18. Anderson JW, Grant L, Gotthelf L, Stifler LT. Weight loss and long-term follow-up of severely obese individuals treated with an intense behavioral program. *Int J Obes (Lond)* 2007;31:488–93.
19. Sumithran P, Proietto J. Safe year-long use of a very-low-calorie diet for the treatment of severe obesity. *Med J Aust* 2008;188:366–68.
20. Lantz H, Peltonen M, Agren L, Torgerson JS. Intermittent versus on-demand use of a very low calorie diet: a randomized 2-year clinical trial. *J Intern Med* 2003;253:463–71.
21. Holes-Lewis KA, Malcolm R, O’Neil PM. Pharmacotherapy of obesity: clinical treatments and considerations. *Am J Med Sci* 2013;345:284–88.
22. Mechanick JI, Youdim A, Jones DB. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. 2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic and Bariatric Surgery. *Surg Obes Relat Dis* 2013;9:159–91.

Table 6. Bariatric surgery: A summary of the characteristics of current conventional procedures²⁴

Surgical procedure	Description	Excess weight loss at 3–5 years*	Percentage mean weight loss	Pattern of weight loss	Morbidity at 1 year	Nutritional concerns
Laparoscopic adjustable gastric banding (LAGB)	Involves placing an adjustable band around the gastroesophageal junction, thereby restricting food intake. The band can be tightened and loosened over time to alter the extent of restriction	54%	20–30%	Gradual; usually maximal at 2–3 years	4.6%	Low (deficiencies in iron, vitamin B12, folate)
Roux-en-Y gastric bypass	Is a combination procedure in which a small stomach pouch is created to restrict food intake and the lower stomach, duodenum and first portion of the jejunum are bypassed to produce modest malabsorption of nutrients and energy intake	60% (75% with banded RYGB)	25–35%	Rapid; maximal at 1–2 years	14.9%	Moderate (deficiencies in iron, vitamin B12, folate, calcium, vitamin D, copper, zinc)
Sleeve gastrectomy	Involves removing the greater portion of the fundus and body of the stomach, reducing its volume from about 2.5 L to about 250 mL	50–60% (limited reports at ≥3 years)	20–30%	Rapid; maximal at 1–2 years	10.8%	Moderate (deficiencies in iron, vitamin B12, folate, calcium, vitamin D, copper, zinc, thiamine)

Contraindications for bariatric surgery: current drug or alcohol abuse; uncontrolled psychiatric illness and lack of comprehension of the risks and benefits, expected outcomes, alternatives and lifestyle changes required with bariatric surgery; the presence or suspicion of esophageal or gastric malignancy; portal hypertension with varices; liver failure; Crohn disease; recently diagnosed malignancy; multiple organ failure; previous gastric or gastrointestinal surgery; recent myocardial infarction (may substantially increase the risk of surgery, later complications or poor outcomes)

* Excess weight defined as the weight of an individual in excess of their weight at BMI 25 kg/m²



23. Buchwald H, Ikramuddin S, Dorman RB, Schone JL, Dixon JB. Management of the metabolic/bariatric surgery patient. *Am J Med* 2011;124:1099–105.
24. Dixon JB, Straznicky NE, Lambert EA, Schlaich MP, Lambert GW. Surgical approaches to the treatment of obesity. *Nat Rev Gastroenterol Hepatol* 2011;8:429–37.
25. Dixon JB, Straznicky NE, Lambert EA, Schlaich MP, Lambert GW. Laparoscopic adjustable gastric banding and other devices for the management of obesity. *Circulation* 2012;126:774–85.
26. Franz MJ, VanWormer JJ, Crain AL, et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. *J Am Diet Assoc* 2007;107:1755–67.
27. Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. *Int J Obes* 2002;26:262–73.
28. Li Z, Maglione M, Ti W, et al. Meta-analysis: pharmacologic treatment of obesity. *Ann Intern Med* 2005;142:532–46.
29. Nieuwenhuis-Ruifrok AE, Kuchenbecker WK, Hoek A, Middleton P, Norman RJ. Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis. *Hum Reprod Update* 2009;15:57–68.
30. Bjorkhem-Bergman L, Asplund AB, Lindh DJ. Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis. *J Psychopharmacol* 2011;25:299–305.
31. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. *BMJ* 2012;344:d7771.
32. Chan EW, He Y, Chui CS, Wong AY, Lau WC, Wong IC. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. *Obes Rev* 2013;14:383–92.
33. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. *Lancet* 2011;377:1341–52.

Follow up requirements	Advantages	Disadvantages
Lifelong (assessment and nutritional support), frequent in the first 12 months	Effective, with good long term weight maintenance Ability to adjust the degree of restriction Reversible Maintains gastric integrity	Gastric pouch dilatation, erosion of band into the stomach, leaks to the LAGB system, weight regain
Lifelong (assessment and nutritional support)	Very effective with good long term weight maintenance Few failures	Abdominal pain, staple line leak, stomach ulcer, intestinal obstruction, gallstones, nutritional deficiency, weight regain
Lifelong (assessment and nutritional support)	Allows for rapid weight loss No dumping syndrome as pyloric portion of the stomach is in tact Provides fixed restriction and does not require adjustment	Staple line leak, gastroesophageal reflux disease, dilatation of the gastric remnant, weight regain

correspondence afp@racgp.org.au